About 9 Trademarks found that are owned by Pebble Labs Inc.

BENCH WORKS

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development of genetically engineered organisms, namely, genetically engineered algae that produce that produce waxes; Research and development of pharmaceuticals, therapeutics, and biologics; Research and development of new biological products for therapeutic use

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit pathogens directed to aquatic organism; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit pathogens directed to aquatic organism grown in aquaculture; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target genes in pathogens affecting to aquatic organisms; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target genes in pathogens affecting to aquatic organisms grown in aquaculture; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes in pathogens affecting to aquatic organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes in pathogens affecting to aquatic organisms grown in aquaculture; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of new biological products for therapeutic use to prevent or treat aquatic diseases; Research and development of new biological products for therapeutic use to prevent or treat diseases affecting animals grown in aquaculture

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of vector-borne pathogen genes; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of vector-borne pathogen genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce interfering molecules that alter mosquito behavior; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce interfering molecules that alter mosquito behavior, namely, the inhibition of a mosquito's appetite and inhibition of a mosquito's olfactory perception; Research and development of new biological products for therapeutic use to prevent or treat vector-borne diseases

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit plant pathogens, pests and herbivores; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target genes in pathogens, pests and herbivores affecting plants; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes in pathogens, pests and herbivores affecting plants; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes in pathogens, pests and herbivores affecting plants; Research and development of new biological products for therapeutic use to prevent or treat diseases, pests, and herbivores that affect plants

Bioinformatic services, namely, software design and development for use in the fields of synthetic biology, molecular biology, genetic engineering and rational biomolecule design; Bioinformatic services, namely, rational design of novel therapeutic compounds and biologics; Bioinformatic services, namely, rational design of novel proteins and receptor interactions; Genomics services and bioinformatics services, namely, genetic sequencing and analysis services; Genomics services and bioinformatics services, namely, genome-wide analysis services; Genomic and bioinformatics services, namely, gene identification; gene expression, protein identification, and protein expression analysis for use in the fields of scientific and research diagnostics, medicine, and biotechnology; Genomic and bioinformatics services, namely, creating genetic and protein sequence libraries for use in the fields of scientific and research diagnostics, medicine, and biotechnology; Scientific laboratory services in the nature of bioinformatic services, namely, genomic and proteomic identification, characterization and analysis in the field of biomedical research; Biotechnology research and bioinformatics services, namely, product research and development in the field of bioinformatics

Medical instruments, namely, biosensors for the detection of pathogens; Medical instruments, namely, biosensor for the detection of pathogens, namely, biosensors for the detection of quorum-sensing molecules produced by pathogens

TRAN BIOLOGICS

Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores

Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores

Cultures of microorganisms other than for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Cultures of microorganisms other than for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in plants, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Cultures of microorganisms other than for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in plants, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions use as ingredients for food and beverages, namely, genetically engineered probiotic bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions for use as ingredients for food and beverages, namely, genetically modified probiotic bacteria configured to produce bioavailable nutritional compounds; Cultures of microorganisms for medical or agricultural use, namely, genetically modified endophytic bacteria for use in therapeutic treatment of pathogens in plants